The “2022 Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with T2DM” recommends metformin alone, or in combination with GLP1 receptor agonists or SGLT2 inhibitors, as a first-line hypoglycemic agent in the absence of explicit contraindications [110]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.